Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORIC Oric Pharmaceuticals Inc.

Trading 04-15 11:07:49 EDT

10.13

-0.40

-3.80%

High10.69	Low10.12	Vol496.78K
Open10.51	D1 Closing10.53	Amplitude5.37%
Mkt Cap1.02B	Tradable Cap876.71M	Total Shares100.36M
T/O5.12M	T/O Rate0.57%	Tradable Shares86.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORIC","market":"US","secType":"STK","nameCN":"Oric Pharmaceuticals Inc.","latestPrice":10.13,"timestamp":1776265661310,"preClose":10.53,"halted":0,"volume":496783,"delay":0,"changeRate":-0.03798670465337119,"floatShares":86545499,"shares":100358200,"eps":-1.47,"marketStatus":"Trading","change":-0.4,"latestTime":"04-15 11:07:49 EDT","open":10.51,"high":10.685,"low":10.12,"amount":5123375.241215,"amplitude":0.053656,"askPrice":10.13,"askSize":2,"bidPrice":10.12,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.47,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776283200000},"marketStatusCode":2,"adr":0,"listingDate":1587700800000,"exchange":"NASDAQ","adjPreClose":10.53,"preHourTrading":{"tag":"盘前","latestPrice":10.63,"preClose":10.53,"latestTime":"09:00 EDT","volume":2,"amount":21.17,"timestamp":1776258040357,"change":0.1,"changeRate":0.009497,"amplitude":0.008547},"postHourTrading":{"tag":"盘后","latestPrice":10.53,"preClose":10.53,"latestTime":"19:59 EDT","volume":65724,"amount":692066.63,"timestamp":1776211142932,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.132773,"impliedVol":0.9029,"impliedVolPercentile":0.548},"requestUrl":"/m/hq/s/ORIC","defaultTab":"news","newsList":[{"id":"2626128170","title":"Why ORIC Pharmaceuticals (ORIC) Is Up 14.2% After Advancing Rinzimetostat Combo Into Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2626128170","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626128170?lang=en_us&edition=fundamental","pubTime":"2026-04-11 15:30","pubTimestamp":1775892655,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals recently reported updated Phase 1b data for its PRC2 inhibitor rinzimetostat (ORIC-944) combined with darolutamide in previously treated metastatic castration-resistant prostate cancer, selecting a 400 mg once-daily regimen as the recommended Phase 3 dose based on efficacy and safety analyses.\nThe company now plans a large global Phase 3 registrational trial targeting an addressable mCRPC market it estimates at over US$3.50 billions in the US and US$7.00 billions...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/why-oric-pharmaceuticals-oric-is-up-142-after-advancing-rinz","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/why-oric-pharmaceuticals-oric-is-up-142-after-advancing-rinz","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625010866","title":"JonesTrading Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625010866","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625010866?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:38","pubTimestamp":1775507926,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy maintained a Buy rating on Oric Pharmaceuticals today and set a price target of $25.00. Roy covers the Healthcare s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-their-buy-rating-for-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-their-buy-rating-for-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624649826","title":"Oric Pharma grants 80,000 stock options in Nasdaq Rule 5635(c)(4) inducement award","url":"https://stock-news.laohu8.com/highlight/detail?id=2624649826","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624649826?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:30","pubTimestamp":1775248216,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals issued inducement equity awards under its 2022 Inducement Equity Incentive Plan for 1 new non-executive employee, dated April 1, 2026.Package included stock options, with 25% vesting at 1 year from grant date, then monthly vesting of remaining balance.Restricted stock units vest in three equal annual installments starting on first anniversary of grant date.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL6GhBRB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4112","SG9999014005.SGD","SG9999014039.USD","BK4139","BK4585","LU2210150020.SGD","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","ORIC","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624566497","title":"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624566497","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624566497?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:30","pubTimestamp":1775248200,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April  03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/03/3268139/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624570485","title":"Analysts Offer Insights on Healthcare Companies: Imunon (IMNN), Axsome Therapeutics (AXSM) and Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624570485","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624570485?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:20","pubTimestamp":1775125212,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Imunon (IMNN), Axsome Therapeutics (AXSM) and Oric P...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-imunon-imnn-axsome-therapeutics-axsm-and-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-imunon-imnn-axsome-therapeutics-axsm-and-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC","LU0029874061.USD","XBI","BK4505","BK4137","BK4007","BK4139","AXSM","BK4581","BK4585","IMNN","LU0128526141.USD","XLV","LABU","BK4588","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624459570","title":"Oric selloff brings attractive entry point, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2624459570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624459570?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:16","pubTimestamp":1775124986,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Robert Burns says the pullback this week in shares of Oric Pharmaceuticals (ORIC) provides an attractive entry point. The f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oric-selloff-brings-attractive-entry-point-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oric-selloff-brings-attractive-entry-point-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624546118","title":"Oric Pharmaceuticals Down Nearly 39%, on Track for Record Percent Decrease -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2624546118","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624546118?lang=en_us&edition=fundamental","pubTime":"2026-04-02 03:24","pubTimestamp":1775071440,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals, Inc.  is currently at $7.74, down $4.93 or 38.91%. --Would be lowest close since May 28, 2025, when it closed at $5.97. --Down 80.55% from its all-time closing high of $39.80 on Dec. 24, 2020. --Up 33.91% from 52 weeks ago , when it closed at $5.78. --Down 46.29% from its 52-week closing high of $14.41 on Oct. 6, 2025. --Up 81.9% from its 52-week closing low of $4.26 on April 8, 2025. --Traded as low as $7.71; lowest intraday level since May 30, 2025, when it hit $7.46. --Down 39.14% at today's intraday low; largest intraday percent decrease since March 22, 2022, when it fell as much as 41.02%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Oric Pharmaceuticals Down Nearly 39%, on Track for Record Percent Decrease -- Data Talk","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624054310","title":"Oric Pharmaceuticals should be bought on selloff, says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2624054310","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624054310?lang=en_us&edition=fundamental","pubTime":"2026-04-02 01:37","pubTimestamp":1775065033,"startTime":"0","endTime":"0","summary":"Citi recommends using today’s weakness in shares of Oric Pharmaceuticals (ORIC) as a buying opportunity. The 30% pullback is “overdone and misguide...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-should-be-bought-on-selloff-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-should-be-bought-on-selloff-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624149605","title":"Oric Pharmaceuticals price target lowered to $17 from $20 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2624149605","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624149605?lang=en_us&edition=fundamental","pubTime":"2026-04-01 22:11","pubTimestamp":1775052700,"startTime":"0","endTime":"0","summary":"Wedbush analyst David Nierengarten lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $17 from $20 and keeps an Outperform rating on...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-price-target-lowered-to-17-from-20-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-price-target-lowered-to-17-from-20-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624511900","title":"Wall Street Set to Open Higher as Trump Says US Will Consider Ceasefire if Hormuz Strait Opened","url":"https://stock-news.laohu8.com/highlight/detail?id=2624511900","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624511900?lang=en_us&edition=fundamental","pubTime":"2026-04-01 21:16","pubTimestamp":1775049397,"startTime":"0","endTime":"0","summary":"US stocks looked set to open higher in Wednesday's trading session after President Trump claimed that the Middle East conflict would be resolved in two to three weeks and that a ceasefire was possible","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PSQ","VTI","MOAT","SCHG","VYM","QQQ","SPLV","BCG","DDM","NQmain","TH","SDS","MGK","SSO","VOOG","QDTE","SPUU","DGRW","NKE",".SPX","GPIQ","SPMO","SPYG","DIA","IVE","QYLG","FTEC","SDOW","SCHD","VUG","DXD","HIBL","SPXS","SPUS","RH","NDX","VOO","JEPI","SPYV","XYLD","QID","ORIC","BMAY","ELAB",".DJI",".IXIC","XLI","ACWI","MYMmain","RSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624516693","title":"Oric Pharmaceuticals Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2624516693","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624516693?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:55","pubTimestamp":1775048100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORIC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2026 08:55 ET (12:55 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624751623","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624751623","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624751623?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:50","pubTimestamp":1775047837,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-diamedica-therapeutics-dmac-elevance-health-elv-and-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-diamedica-therapeutics-dmac-elevance-health-elv-and-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0878866978.SGD","LU0068578508.USD","LU1720051017.SGD","LU0345770308.USD","LU2362541273.HKD","LU0208291251.USD","LU1720051108.HKD","LU2357305700.SGD","LU0289739699.SGD","LU0211331839.USD","HCSG","BK4585","LU0029874061.USD","LU2362540622.SGD","LU2505996509.AUD","XLV","LU0320765489.SGD","LU2430703095.HKD","LU0648001328.SGD","SGXZ23171101.USD","LU0251142724.SGD","LU0345770993.USD","LU0128526141.USD","ORIC","LU1057294990.SGD","LU1201861249.SGD","LU0106261372.USD","LU0314106906.USD","XBI","DMAC","ELV","LU0114720955.EUR","LU0557290698.USD","LU0957791311.USD","LU0640476718.USD","LU2362541513.USD","LU1983299246.USD","LU1489326972.SGD","LABU","LU2108987350.USD","BK4581","LU0266013472.USD","LU0058720904.USD","LU0742534661.SGD","LU0477156953.USD","LU0006306889.USD","SG9999003800.SGD","LU1815333072.USD","LU0130102774.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624513041","title":"Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2624513041","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624513041?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:16","pubTimestamp":1775045796,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Cory Kasimov maintained a Buy rating on Oric Pharmaceuticals today and set a price target of $25.00. According to TipRanks, Ka...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oric-pharmaceuticals-oric-receives-a-buy-from-evercore-isi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oric-pharmaceuticals-oric-receives-a-buy-from-evercore-isi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624851395","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2624851395","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624851395?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:06","pubTimestamp":1775045196,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals  shares were down 22% in recent Wednesday premarket activity, shaving Tuesday's gain.RH  stock was down 20%, a day after the company posted lower fiscal Q4 adjusted earnings that also missed analysts' forecasts.Nike  shares were 12% lower after the sports apparel maker reported overnight lower fiscal Q3 earnings.Beyond Meat  stock was down 7% after the company posted Tuesday lower Q4 revenue in addition to issuing Q1 revenue outlook that trailed analysts' estimates.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4178","LU0823411888.USD","BK4559","BK4146","BK4212","LU1267930573.SGD","BK4588","LU1303367103.USD","LU2098885051.SGD","NKE","LU0310800379.SGD","BK4548","IE00BFXG0V08.USD","LU0786609619.USD","LU0708994859.HKD","BK4581","RH","LU0792757196.USD","LU1267930813.SGD","ORIC","BK4139","BK4534","LU0029864427.USD","BK4566","BK4561","IE00BYQQ9H92.USD","BK4558","BK4533","LU0128525929.USD","LU0889566641.SGD","BYND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590111","title":"Guggenheim Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590111","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590111?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:15","pubTimestamp":1775042139,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Bradley Canino maintained a Buy rating on Oric Pharmaceuticals yesterday and set a price target of $18.00. The company’s shares ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624951597","title":"Wedbush Cuts Price Target on ORIC Pharmaceuticals to $17 From $20, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2624951597","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624951597?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:00","pubTimestamp":1775041205,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals (ORIC) has an average rating of buy and mean price target of $21, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624026594","title":"Oric Pharmaceuticals Shares Fall on Side Effect Data in Prostate Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2624026594","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624026594?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:22","pubTimestamp":1775038920,"startTime":"0","endTime":"0","summary":"Shares of Oric Pharmaceuticals fell after the company said data from a phase 1b trial of a prostate cancer treatment showed that a larger dose led to higher rates of side effects.Shares were down 22% to $9.91 in pre-market trading Wednesday after closing Tuesday at $12.67. At close, the stock had more than doubled in value over the past year.The company on Tuesday reported data from a trial of rinzimetostat in combination with darolutamide to treat patients with metastatic castration-resistant prostate cancer who have previously taken abiraterone acetate. It tested 400 milligram and 600 milligram doses of rinzimetostat.The larger dose \"was associated with a modestly higher rate of adverse events and dose modifications,\" the company said.Oric said it is prepared to move forward with phase 3 trials for the treatment at a 400 milligram dose, adding that the first phase 3 trial is expected to launch in the first half of this year.\"In contrast, the E-R analysis identified statistically sign","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624756770","title":"ORIC Pharmaceuticals Stock Nosedives 25% After Hours: What Is Going On?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624756770","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624756770?lang=en_us&edition=fundamental","pubTime":"2026-04-01 14:48","pubTimestamp":1775026080,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals stock rose after reporting positive cancer drug data and advancing to a Phase 3 trial, before falling sharply in after-hours trading.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/01/Medication-In-Transparent-Capsules-On-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/01/Medication-In-Transparent-Capsules-On-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/04/51590748/oric-pharmaceuticals-stock-nosedives-25-percent-after-hours-what-is-going-on","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/04/51590748/oric-pharmaceuticals-stock-nosedives-25-percent-after-hours-what-is-going-on","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624565014","title":"Oric Advances Rinzimetostat Toward First Prostate Cancer Phase 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2624565014","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624565014?lang=en_us&edition=fundamental","pubTime":"2026-04-01 11:38","pubTimestamp":1775014695,"startTime":"0","endTime":"0","summary":"An announcement from Oric Pharmaceuticals ( ($ORIC) ) is now available. On March 31, 2026, ORIC Pharmaceuticals presented an update on dose optimiz...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oric-advances-rinzimetostat-toward-first-prostate-cancer-phase-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oric-advances-rinzimetostat-toward-first-prostate-cancer-phase-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126788829","title":"24H｜DEFT Soared 50%; NCino Surged 20%; Oric Pharmaceuticals Plunged 25%; Battalion Oil Down 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126788829","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126788829?lang=en_us&edition=fundamental","pubTime":"2026-04-01 09:50","pubTimestamp":1775008234,"startTime":"0","endTime":"0","summary":"Crypto Shares Rally. DEFT up 50%; ALTS and ORBS up 4%; DeFi and UPXI up 3%.Shares of $nCino(NCNO)$ were trading 20% higher in overnight trading as it had fourth-quarter earnings per share of 7 cents...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"330240692f324d079ccf839d9e4180bf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","NCNO","OXY","BATL","BK4023","BK4139","BK4559","BK4588","BK4585","BK4201","ORIC"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.oricpharma.com","stockEarnings":[{"period":"1week","weight":0.1871},{"period":"1month","weight":-0.1151},{"period":"3month","weight":-0.064},{"period":"6month","weight":-0.2083},{"period":"1year","weight":1.0607},{"period":"ytd","weight":0.2873}],"compareEarnings":[{"period":"1week","weight":0.0535},{"period":"1month","weight":0.0486},{"period":"3month","weight":0.0059},{"period":"6month","weight":0.0512},{"period":"1year","weight":0.2881},{"period":"ytd","weight":0.0184}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.039993},{"month":2,"riseRate":0.5,"avgChangeRate":-0.014475},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.092137},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.164964},{"month":5,"riseRate":0.666667,"avgChangeRate":0.07899},{"month":6,"riseRate":0.666667,"avgChangeRate":0.141043},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.000511},{"month":8,"riseRate":0.666667,"avgChangeRate":0.090659},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.048915},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.0811},{"month":11,"riseRate":0.666667,"avgChangeRate":0.167402},{"month":12,"riseRate":0.5,"avgChangeRate":0.06155}],"exchange":"NASDAQ","name":"Oric Pharmaceuticals Inc.","nameEN":"Oric Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oric Pharmaceuticals Inc.,ORIC,Oric Pharmaceuticals Inc.股票,Oric Pharmaceuticals Inc.股票老虎,Oric Pharmaceuticals Inc.股票老虎国际,Oric Pharmaceuticals Inc.行情,Oric Pharmaceuticals Inc.股票行情,Oric Pharmaceuticals Inc.股价,Oric Pharmaceuticals Inc.股市,Oric Pharmaceuticals Inc.股票价格,Oric Pharmaceuticals Inc.股票交易,Oric Pharmaceuticals Inc.股票购买,Oric Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction